BiliaryTractCancer near Morristown, NJ

Care Philosophy: Terenig Terjanian, MD, is a hematologist and medical oncologist at Northwell Health, and an assistant professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Growing up in Lebanon, Dr. Terjanians early love for biology and chemistry set him on the path toward medicine. After attending St. Josephs University, he did a residency in pathology at American University of Beirut Medical Center, and one in internal medicine at Staten Island University Hospital. He then did fellowships in hematology and oncology at NYU Grossman School of Medicine and University of Texas MD Anderson Cancer Center. Although he initially specialized in pathology, Dr. Terjanian chose cancer care as a main focus after coming to the United States in 1981. ``The number one thing I want patients to know is that I'll listen to them,`` he says. ``I try to go over every aspect of their disease slowly, explain why we order the tests we do, and have them be completely aware of all the steps,`` he says, adding that he often gives patients his cell number, because he knows concerns can come up anytime. ``I think of what I would want as a patient, and it would be a doctor who really cares.`` Dr. Terjanian is deeply interested in clinical research. He has been the principal investigator on several protocols, including those of the National Surgical Adjuvant Breast and Bowel Project at Staten Island University Hospital, and has published multiple peer-reviewed papers and abstracts and presented at international meetings. He also runs the research committee for medical residents interested in hematology-oncology, and for fellows in that specialty. He's a member of the system-wide Institutional Review Board, a group that ensures clinical trials are done ethically and safely. In addition to participation in weekly tumor board meetings, and frequently providing lectures for interns and residents, Dr. Terjanian still enjoys the chemistry and biology that drew him to medicine from the start, especially since the science in oncology changes so rapidly which leads to improved patient outcomes. ``Every day, there is something new happening in cancer diagnosis and treatment, and it's exciting to see that progress,`` he says. ``Patients are living longer, they're experiencing better quality of life with targeted therapy or immunotherapy. Its immensely satisfying to see how far we've come.``

Biography: Dr. Brett Ecker, MD is a Complex General Surgical Oncology Specialist who practices in Livingston, NJ. He is 38 years old. Dr. Brett Ecker, MD is affiliated with Cooperman Barnabas Medical Center and Robert Wood Johnson University Hospital.

Care Philosophy: Dr. Schor is the Director of Vascular and Endovascular Surgery at Staten Island University Hospital and an Associate Professor of Surgery at Hofstra/Northwell School of Medicine. He is Board Certified in both Vascular and General Surgery. He completed his general surgical training at New York University and completed his vascular training at Rutgers/ New Jersey Medical School. Dr. Schor has participated in both clinical and basic science research that has been presented at local and national scientific meetings. He has a special interest in endovascular treatments of aortic aneurysm, peripheral vascular disease and venous disorders.Dr. Schor is co-director of the Staten Island University Hospital Aortic Center. The Aortic Center is a multi-specialty center for treatment of aortic pathology. He performed the first fully percutaneous treatment for abdominal aortic aneurysm on Staten Island in 2010. Dr. Schor also performed the first Transcarotid Artery Revascularization (TCAR) procedure on Staten Island for the treatment of carotid artery disease. Dr. Schor is interested in the treatment of peripheral vascular disease, venous disease and abdominal aortic aneurysm. Dr. Schor is a member of Society of Vascular Surgery, Eastern Vascular Society, American Venous Forum, and is a Fellow of the American College of Surgeons. He has a research interest in the surgical management of DVT and treatment of PVD. Dr. Schor is a principal investigator for a number of National Institute of Health (NIH) sponsored clinical research trials, and his research has been presented at both local and national meetings.